



SPAFID
CONNECT

Informazione Regolamentata n. 20106-40-2021	Data/Ora Ricezione 25 Agosto 2021 08:23:29	MTA - Star
---	--	------------

Societa' : PHARMANUTRA
Identificativo : 151315
Informazione
Regolamentata
Nome utilizzatore : PHARMANUTRAN02 - Lacorte Roberto
Tipologia : REGEM
Data/Ora Ricezione : 25 Agosto 2021 08:23:29
Data/Ora Inizio : 25 Agosto 2021 08:23:30
Diffusione presunta
Oggetto : PR - PHARMANUTRA Cetilar patent
granted in China

Testo del comunicato

Vedi allegato.

PHARMANUTRA S.P.A. OBTAINS THE GRANT OF CETILAR® PATENT IN CHINA

PharmaNutra has received confirmation from the Chinese authorities of obtaining the patent for Cetylated Fatty Acids (CFAs), the innovative active ingredient contained in products of the Cetilar® line.

Pisa, 25 August 2021 - [PharmaNutra S.p.A.](#) (MTA; Ticket PHN), a company specialized in nutritional supplements containing iron and minerals and medical devices for muscles and joints, is pleased to announce that it has obtained an important new strategic asset: the company has obtained the granting of the patent for formulas containing cetylated fatty acids (CFAs) in China.

The patent, granted on 03/08/2021 with number CN 108137472 B, is referred to the development and use of topical formulas containing cetylated fatty acids, the active ingredient included in all the products for muscles and joints in the Cetilar® line.

The granting of this patent will allow PharmaNutra Group to begin working on a new plan to boost its business on the wide Chinese market while expanding and setting up potential new partnerships in Asia.

"Confirmation of this outstanding result requires us to speed up the assessment of business prospects and the rapid penetration of previously unexplored markets. The obtainment of the patent in China is an important result considering also that the protection of intellectual property rights is particularly challenging in Asian markets; this is why we are particularly anxious to explore new business prospects in the area in the near future," **comments Andrea Lacorte, President of PharmaNutra S.p.A.**

The development of patents based on the complex of highly concentrated cetylated fatty acids (CFAs) has made PharmaNutra S.p.A. - already operating in seven countries with its own brand Cetilar® - an emerging top player on the market for medical devices for rehabilitation of joint capability.

PharmaNutra S.p.A.

Founded and led by President Andrea Lacorte and Deputy President Roberto Lacorte, PharmaNutra, established in 2003, develops unique nutraceuticals and innovative medical devices, overseeing the entire production process from the proprietary raw materials to the finished product. The effectiveness of its products has been demonstrated by extensive scientific evidence, including more than 140 published papers. The Group has distribution and sales operations in Italy and abroad. In Italy, sales are conducted through a network of more than 150 medical representatives, who also handle exclusive marketing of PharmaNutra products to pharmacies all over the country. International sales in more than 50 countries are managed through 39 partners selected from top pharmaceutical companies. PharmaNutra is the leading producer of SiderAL®, iron-based nutritional supplements, an area where it holds important patents for Sucrosomial® Technology. Over the years, the Group has developed a specific intellectual property production and management strategy, based on integrated management of all components: proprietary raw materials, patents, trademarks and clinical data.

PharmaNutra.it

For further information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b - 56122 Pisa

Tel. +39 050 7846500

investorrelation@PharmaNutra.it

Internal Press Office

press@calabughi.com

Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan

Tel. +39 02 83635708

Matteo Russo

mrusso@sprianocommunication.com

Cristina Tronconi

ctronconi@sprianocommunication.com

Fine Comunicato n.20106-40

Numero di Pagine: 4